purpos
irrevers
electropor
ire
demonstr
safe
effect
method
local
advanc
pancreat
cancer
lapc
aim
studi
evalu
immunomodulatori
effect
ire
evalu
prognost
valu
variat
immun
paramet
lapc
patient
ire
method
peripher
blood
sampl
patient
obtain
preoper
third
day
seventh
day
ire
respect
phenotyp
lymphocyt
analyz
flow
cytometri
dynam
chang
serum
level
cytokin
complement
immunoglobulin
assay
enzymelink
immunosorb
assay
receiv
oper
characterist
roc
curv
concord
index
cindex
use
compar
surviv
predict
abil
result
transitori
decreas
follow
steadi
increas
cell
cell
nk
cell
igg
revers
trend
detect
treg
cell
ire
alter
cell
identifi
prognost
factor
overal
surviv
os
progressionfre
surviv
pf
valu
roc
curv
auc
cindex
alter
cell
os
pf
respect
larger
immun
inflammationbas
index
conclus
studi
present
first
evid
irebas
immunomodulatori
patient
lapc
alter
cell
show
rel
good
perform
could
use
effect
tool
prognost
evalu
lapc
patient
ire
pancreat
adenocarcinoma
lethal
diseas
extrem
poor
prognosi
also
repres
seventh
sixth
lead
caus
cancerrel
death
world
china
respect
surviv
rate
surgic
resect
chanc
obtain
cur
treatment
suitabl
less
patient
diseas
approxim
new
case
diagnos
local
advanc
pancreat
cancer
lapc
character
involv
major
vascular
structur
celiac
trunk
superior
mesenter
arteri
lead
unresect
nonmetastat
diseas
current
treatment
lapc
remain
huge
challeng
due
poor
prognos
diseas
limit
respons
littl
impact
surviv
life
achiev
standard
treatment
mainli
system
chemotherapi
moreov
high
rate
advers
event
due
toxic
chemotherapi
limit
use
promot
treatment
combin
chemotherapi
leucovorin
irinotecan
oxaliplatin
folfirinox
even
though
shown
display
progress
improv
surviv
patient
lapc
therefor
necessari
evalu
new
treatment
optim
common
therapeut
approach
nowaday
local
therapi
shown
improv
prognosi
lapc
patient
vari
degre
success
journal
oncolog
irrevers
electropor
ire
nontherm
ablat
techniqu
establish
local
abl
therapi
patient
lapc
promis
outcom
increas
overal
surviv
os
month
month
novel
local
destruct
method
base
transmiss
high
voltag
current
tumor
via
needl
lead
cell
membran
defect
apoptot
death
addit
induct
process
apoptot
death
ire
structur
composit
tumor
microenviron
chang
induc
intens
inflammatori
cell
respons
character
infiltr
immun
cell
shown
ireinduc
immunomodulatori
limit
ablat
area
also
system
reaction
thu
ire
could
regard
potenti
immunomodulatori
treatment
might
induc
extens
chang
immun
cell
index
ablat
far
data
rare
predict
factor
ire
outcom
patient
lapc
novel
power
treatment
lapc
prognost
marker
urgent
need
choos
patient
rel
better
prognosi
moreov
earli
inform
efficaci
treatment
first
day
ire
would
highli
appreci
therapi
may
intensifi
treatment
immun
therapi
chemotherapi
radiotherapi
regular
evalu
therapi
imag
done
month
ire
treatment
candid
predict
factor
circul
biochem
marker
may
promis
one
relationship
cancer
diseas
immedi
therapi
effect
immunolog
respons
organ
treatment
importantli
failur
achiev
immunecheckpoint
therapi
pancreat
cancer
due
low
rate
neoantigen
express
mutat
event
explor
alter
evalu
prognost
effect
immun
cell
index
might
open
prospect
use
immunecheckpoint
therapi
patient
lapc
immunomodulatori
effect
ire
examin
analyz
alter
sever
immun
cell
index
patient
lapc
aim
evalu
respons
ire
therapi
earli
treatment
phase
identifi
role
prognosi
patient
studi
retrospect
design
consecut
patient
newli
diagnos
lapc
sun
yatsen
univers
cancer
center
august
august
includ
studi
inclus
criteria
follow
patholog
confirm
pancreat
adenocarcinoma
radiolog
confirm
lapc
lapc
defin
per
seventh
edit
ajcc
stage
system
pancreat
cancer
describ
lapc
arteri
encas
either
celiac
axi
superior
mesenter
arteri
unreconstruct
superior
mesenter
portal
vein
involv
evid
metastat
diseas
abdomin
thorac
comput
tomographi
ire
therapi
initi
treatment
total
patient
exclud
base
follow
exclus
criteria
treatment
includ
surgic
resect
rfa
ire
seven
patient
exist
metastat
implant
ire
one
patient
heart
arrhythmia
histori
second
primari
malign
tumor
one
patient
miss
inform
paramet
lost
followup
two
patient
studi
approv
institut
review
board
sun
yatsen
univers
cancer
center
procedur
perform
present
studi
involv
human
particip
accord
ethic
standard
institut
andor
nation
research
committe
helsinki
declar
later
amend
similar
ethic
standard
written
inform
consent
obtain
patient
prior
treatment
clinic
data
collect
follow
clinic
radiolog
data
retriev
medic
record
archiv
sun
yatsen
univers
cancer
center
includ
age
gender
tumor
size
tumor
grade
tumor
site
white
blood
cell
wbc
count
platelet
plt
count
serum
level
alanin
transaminas
alt
aspart
aminotransferas
ast
alkalin
phosphatas
alp
glutamyl
transpeptidas
ggt
albumin
alb
total
bilirubin
tbil
indirect
bilirubin
ibil
creactiv
protein
crp
carcinoembryon
antigen
cea
carbohydr
antigen
inflammationbas
index
includ
neutrophiltolymphocyt
ratio
nlr
platelettolymphocyt
ratio
plr
prognost
index
pi
modifi
glasgow
prognost
score
mgp
also
enter
studi
threshold
clinic
radiolog
variabl
use
cutoff
valu
cutoff
valu
nlr
plr
associ
optim
youden
index
os
progressionfre
surviv
pf
predict
respect
defin
score
inflammationbas
index
pi
mgp
describ
previou
studi
treatment
procedur
nanoknif
ire
equip
angiodynam
system
queensburi
ny
usa
use
gener
anesthesia
deep
neuromuscular
block
adopt
creat
electr
field
around
tumor
probe
use
accord
size
locat
tumor
ultrasound
use
guid
placement
probe
adequ
space
probe
confirm
gener
unit
softwar
use
analyz
probe
configur
data
ultrasound
provid
optim
voltag
puls
length
deliveri
tumor
size
larger
cm
axial
plane
pullback
techniqu
procedur
perform
cover
entir
area
ablat
sampl
collect
blood
sampl
collect
hypothesi
studi
known
blood
sampl
collect
use
naheparin
plasma
tube
enrol
patient
ire
preop
day
ire
isol
peripher
blood
mononuclear
cell
pbmc
process
immedi
use
hypaqueficol
promega
frozen
liquid
nitrogen
vv
plu
vv
autolog
serum
flow
cytometri
analysi
frozen
pbmc
thaw
c
water
bath
cultur
overnight
c
gibco
brl
supplement
human
ab
type
serum
label
fitc
apc
andor
peconjug
murin
antihuman
monoclon
antibodi
phenotyp
lymphocyt
sequenti
analyz
flow
cytometri
fac
calib
color
system
bd
bioscienc
ca
us
assay
immun
paramet
quantit
sandwich
enzym
immunoassay
techniqu
elisa
kit
r
system
minneapoli
mn
adopt
measur
serum
concentr
cytokin
includ
interferon
ifn
tumornecrosi
factor
tnf
procedur
measur
l
assay
diluent
ad
polystyren
micropl
precoat
murin
monoclon
antibodi
ifn
tnf
serum
sampl
incub
c
hour
plate
aspir
wash
three
time
incub
repeat
micolit
conjug
ad
plate
incub
c
minut
l
substrat
solut
ad
final
l
stop
solut
ad
plate
micropl
reader
clinicalbio
austria
use
read
optim
densiti
od
within
minut
nm
wavelength
whose
refer
set
nm
beckman
array
system
beckman
coulter
galway
ireland
use
evalu
concentr
sever
humor
immun
paramet
includ
iga
igm
igg
specif
antibodi
measur
enzymelink
immunosorb
assay
elisa
incub
micropl
reader
clinicalbio
austria
use
read
od
within
minut
nm
wavelength
whose
refer
set
nm
followup
followup
procedur
perform
accord
previou
public
recommend
os
defin
durat
treatment
death
last
followup
pf
defin
durat
treatment
date
diseas
progress
diagnos
last
followup
last
followup
complet
septemb
statist
analysi
continu
variabl
compar
use
independ
sampl
ttest
mannwhitney
u
test
binari
categor
variabl
compar
use
chisquar
test
os
pf
curv
analyz
use
kaplanmei
method
differ
group
identifi
use
logrank
test
univari
analysi
perform
assess
signific
paramet
multivari
analysi
perform
use
cox
regress
model
variabl
found
signific
univari
analysi
correspond
confid
interv
ci
calcul
roc
curv
cindex
use
compar
surviv
predict
abil
twotail
p
valu
consid
statist
signific
statist
analys
perform
use
r
statist
packag
r
softwar
version
r
foundat
statist
comput
vienna
austria
patient
characterist
present
studi
total
patient
lapc
retrospect
includ
studi
patient
receiv
ire
therapi
femal
patient
male
patient
median
age
year
rang
year
patient
characterist
summar
tabl
larg
size
moder
differenti
commonli
seen
featur
tumor
patient
lower
valu
inflammatori
index
plr
pi
mgp
patient
higher
valu
nlr
occupi
major
patient
whole
studi
cohort
patient
whose
tbil
higher
umol
complic
ire
treatment
patient
lapc
also
evalu
tabl
frequent
report
complic
pain
patient
hypotens
patient
modul
circul
immun
cell
investig
ire
influenc
circul
immun
cell
cell
phenotyp
character
evalu
absolut
number
helper
cell
cell
identifi
cytotox
cell
cell
identifi
regulatori
cell
treg
identifi
natur
killer
cell
nk
cell
identifi
preop
ire
treatment
shown
absolut
number
cell
p
cell
p
nk
cell
p
decreas
immedi
ire
follow
steadi
increas
next
day
p
howev
trend
treg
cell
revers
preop
p
nk
cell
show
dramat
invers
effect
time
interv
huge
alter
cell
cell
observ
signific
decreas
ratio
cell
cell
p
figur
immun
paramet
complet
understand
ireassoci
alter
immun
analys
plasma
concentr
sever
cytokin
conduct
mark
chang
observ
p
p
p
ire
dramat
increas
circul
decreas
p
although
chang
observ
signific
increas
p
contrari
ire
significantli
alter
plasma
concentr
ifnand
tnf
p
moreov
analyz
plasma
concentr
sever
gener
humor
immun
paramet
complement
immunoglobulin
iga
igg
igm
igg
notabl
decreas
immedi
ire
p
significantli
increas
within
one
week
p
signific
chang
concentr
iga
igm
p
figur
abbrevi
tabl
comparison
surviv
stratifi
chang
immun
cell
paramet
whole
studi
cohort
patient
aliv
end
followup
cumul
os
rate
respect
evalu
prognost
valu
immun
cell
paramet
elev
decreas
group
variabl
defin
threshold
median
valu
alter
subgroup
analys
os
patient
increas
cell
cell
p
nk
cell
decreas
treg
cell
signific
better
os
other
signific
differ
regard
os
stratifi
chang
cytokin
includ
p
addit
variabl
alter
igg
lead
signific
differ
os
p
figur
regard
pf
signific
surviv
benefit
could
obtain
increas
cell
alter
immun
cell
paramet
significantli
associ
pf
figur
cox
regress
analysi
increas
cell
associ
increas
os
pf
cell
os
pf
predict
respect
higher
immun
paramet
inflammationbas
index
tabl
term
comparison
cindex
os
predict
valu
alter
cell
ci
higher
factor
term
pf
predict
cell
also
display
rel
high
valu
ci
show
signific
better
predict
power
tabl
studi
immunomodulatori
effect
demonstr
alter
lymphocyt
cytokin
humor
immun
paramet
patient
lapc
ire
first
evid
irebas
immun
modul
lapc
patient
shown
transitori
decreas
follow
steadi
increas
cell
cell
nk
cell
igg
revers
trend
observ
journal
oncolog
tabl
journal
oncolog
tabl
journal
oncolog
abbrevi
tabl
treg
cell
ire
circul
cytokin
includ
tnf
ifn
also
evalu
term
ifn
ifnplay
import
role
immunostimulatori
immunomodulatori
effect
compar
abil
inhibit
viral
replic
directli
main
function
ifn
therefor
ifnand
tnf
analyz
fail
show
obviou
alter
addit
alter
cell
identifi
prognost
factor
os
pf
first
show
conveni
effect
prognost
valu
patient
lapc
ire
compar
tradit
inflammationbas
score
alter
cell
exhibit
better
predict
valu
os
pf
lapc
patient
ablat
therapi
sever
studi
reveal
chang
individu
count
cell
subset
ratio
alessandro
g
et
al
compar
concentr
cell
radiofrequ
ablat
rfa
reveal
increas
abovement
cell
third
day
treatment
studi
conduct
ketevan
et
al
signific
decreas
express
cell
observ
rfa
compar
oper
anim
studi
ire
therapi
induc
increas
tumor
infiltr
cell
report
effect
immunocompet
tumor
immunocompromis
tumor
furthermor
martin
et
al
report
ire
induc
obviou
decreas
absolut
number
treg
cell
patient
lapc
similar
martin
studi
studi
show
transitori
increas
follow
remark
decreas
treg
cell
along
steadi
increas
effect
cell
humor
immun
paramet
ire
inflammationinduc
treatment
ire
directli
destroy
tumor
cell
also
result
releas
tumorassoci
neoantigen
may
stimul
cellular
humor
immun
bodi
number
immunocyt
product
humor
immun
paramet
increas
due
potenti
cellular
humor
immun
moreov
shown
heatshock
protein
releas
destroy
tumor
cell
adjuv
effect
act
alarm
antitumor
cellmedi
immun
therefor
ire
may
mean
signific
effort
overcom
immunosuppress
cold
tumor
microenviron
lapc
potenti
treatment
window
opportun
immunecheckpoint
therapi
suggest
increas
effector
cell
decreas
immunosuppress
treg
cell
addit
patient
prior
biliari
drainag
procedur
hepaticojejunostomi
open
procedur
perform
also
seriou
complic
abdomin
infect
pancreat
fistula
observ
patient
ire
therapi
therefor
influenc
hyperbilirubinemia
infect
ire
alter
immun
cell
minim
although
detain
chang
immun
cell
describ
patient
lapc
ire
clinic
perform
chang
surviv
predict
still
unclear
therebi
limit
valu
next
step
present
studi
evalu
prognost
factor
os
pf
show
elev
cell
associ
favour
os
pf
lapc
patient
ire
explain
stimul
host
immun
respons
might
limit
progress
invas
tumor
therefor
better
surviv
achiev
prove
previou
studi
strong
relationship
observ
immun
toxic
metastasi
metastas
frequent
observ
patient
lower
densiti
immun
effector
cell
accord
result
furthermor
predict
power
alter
sever
immun
cell
inflammationbas
index
compar
studi
demonstr
alter
cell
superior
index
addit
robust
econom
method
alter
cell
obtain
peripher
blood
sampl
fast
easili
use
wide
clinic
practic
although
correl
immun
cell
inflammationbas
index
alter
cell
could
still
provid
addit
prognost
valu
patient
level
inflammationassoci
situat
mayb
consid
complement
predict
prognosi
lapc
patient
ire
howev
slightli
lower
valu
auc
cell
pf
predict
suggest
compar
pf
mayb
os
affect
greatli
chang
immun
system
differ
tumorinfiltr
cell
shown
play
import
role
determin
local
progress
compar
prognosi
lapc
system
diseas
local
diseas
present
studi
peripher
blood
sampl
collect
ire
treatment
analyz
flow
cytometri
cell
therefor
thought
human
immun
system
play
import
role
longterm
surviv
local
control
similar
present
studi
studi
conduct
chen
et
al
shown
alter
cell
independ
prognost
factor
os
pf
may
partli
explain
differ
impact
surviv
alter
cell
howev
differ
need
explor
studi
comparison
auc
cindex
alter
immun
cell
inflammationbas
index
conduct
although
alter
cell
exhibit
signific
effect
predict
surviv
statist
signific
observ
differ
alter
cell
index
impli
need
improv
predict
shortterm
surviv
chang
immun
cell
mayb
magnitud
effector
cell
posit
associ
longterm
surviv
shortterm
surviv
first
studi
compar
chang
immunocyt
explor
prognost
power
chang
patient
lapc
ire
studi
limit
small
size
retrospect
natur
immunocyt
measur
studi
repres
compon
microenviron
lapc
ire
therapi
moreov
mayb
necessari
analyz
immun
paramet
withdrawn
moment
progress
longer
followup
period
also
need
comparison
effect
